What Dako Denmark does

Dako Denmark is a provider of reagents, instruments, and software solutions for cancer diagnostics, serving hospital and independent clinical pathology laboratories, research institutions, and pathologists/clinicians globally. The company was founded in 1996 and is headquartered in Glostrup, Denmark, and currently operates as a wholly-owned brand of Agilent Technologies (NYSE: A), with its commercial and distribution functions delivered through Agilent's global enterprise sales, e-commerce, and distributor infrastructure. Its product portfolio centers on the complete pathology workflow and includes Hematoxylin & Eosin (H&E) staining solutions, immunohistochemistry (IHC) and in situ hybridization (ISH) reagents, special stains, molecular pathology assays, clinical flow cytometry reagents, diagnostic antibodies and specific protein reagents, FDA-approved companion diagnostics under the PharmDx brand, digital pathology software, and OEM antibodies supplied to third-party diagnostic instrument manufacturers. Instrument lines such as the Artisan Link special-stains system anchor recurring consumables pull-through.

Dako makes money through a mix of capital instrument sales (staining systems, imaging platforms, digital pathology hardware), high-margin recurring reagent and antibody consumables, companion diagnostic test sales tied to targeted oncology therapies, software/informatics subscriptions for digital pathology and lab workflow management, and multi-year service and support contracts. Pricing is quote-based rather than list, reflecting the enterprise laboratory procurement model with multi-year contracts. The company's go-to-market relies on Agilent's direct enterprise field sales targeting large hospital systems and reference laboratories, supplemented by online ordering, quote requests, and a regional distributor network. Marketing reach is delivered through Dako Academy (instrument training), Pathology Education (continuing education), Agilent University, webinars, worldwide trade shows, and technical content resources. Strategic positioning is reinforced by FDA-approved companion diagnostics, an established pathology brand trusted by clinical laboratories worldwide, and embedded validated workflows that generate meaningful switching costs across the clinical lab customer base.

Name

Dako Denmark

Legal name

Dako Denmark

Website

https://dako.com

Company type

Private

Founded year

1996

Operating status

Operating

Headcount range

5,001–10,000 employees

Short description

Dako Denmark provides cancer diagnostic reagents, instruments, and software—including IHC/ISH, companion diagnostics, and flow cytometry—to clinical and research laboratories worldwide, operating as a wholly-owned Agilent Technologies brand.

Ownership category

akta.pro rank

Headquarters

HQ city

Glostrup

HQ country

Denmark

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Diagnostic Instruments and Equipment: Sale of pathology instruments including staining systems, imaging platforms, and digital pathology solutions
2. Diagnostic Reagents and Antibodies: Recurring revenue from high-quality diagnostic antibodies, reagents, and consumables used in clinical laboratories worldwide
3. Companion Diagnostics: Specialized diagnostic tests that guide targeted therapy selection for cancer treatment, often sold directly to clinical laboratories and hospitals
4. Software and Informatics: Digital pathology software solutions for image analysis and laboratory workflow management
5. Service and Support: Instrument maintenance, repair, and technical support services for clinical laboratory customers

Pricing tiers

Go-to-market motion1 record

Distribution channels3 records

Marketing channels6 records

Core offering

Dako Denmark manufactures and supplies diagnostic reagents, antibodies, instruments, and software for cancer pathology. Its portfolio spans immunohistochemistry (IHC), in situ hybridization (ISH), H&E staining, special stains, molecular pathology, clinical flow cytometry, specific protein detection, and FDA-approved companion diagnostics (PharmDx). Products are sold to clinical laboratories, hospitals, and research institutions globally through Agilent's direct sales, online ordering, and distributor channels.

Product overview

Dako, now part of Agilent Technologies, is a comprehensive pathology solutions provider offering a portfolio of high-quality diagnostic antibodies, reagents, instruments, software, and expertise for clinical laboratories worldwide. The Dako product ecosystem centers on cancer diagnostics, combining H&E staining, IHC/ISH molecular pathology tools, special stains, companion diagnostics, and flow cytometry reagents. The core product lines include Dako H&E for histological staining, Dako IHC and ISH for biomarker detection, Dako Special Stains for enhanced tissue visualization, Dako Companion Diagnostics for targeted therapy selection, Dako Molecular pathology solutions, Dako Antibodies and Specific Proteins for diagnostic testing, and Dako Flow Cytometry for cell analysis. OEM Antibodies are available for third-party integration. Dako Academy provides instrument training and workshops to support these product lines.

Differentiator

Problem solved

Functional benefit

Brands

• Dako Academy: Instrument training and workshops offered by Dako for customers using Dako products and diagnostic instruments.
• Dako Products

Products and services

• Dako H&E (Hematoxylin & Eosin) Hematoxylin and eosin staining solutions used in histology for visualizing tissue structures and diagnosing diseases, supporting pathologists in making accurate cancer diagnoses.
• Dako IHC and ISH (Immunohistochemistry and In Situ Hybridization) Immunohistochemistry and in situ hybridization reagents and instruments for detecting specific antigens and nucleic acids in tissue samples, enabling precise cancer diagnostics and biomarker analysis in clinical laboratories.
• Dako Special Stains Special staining reagents and instruments for enhanced tissue visualization and diagnostic differentiation beyond standard H&E staining, supporting detailed pathological analysis in clinical laboratories.
• Dako Companion Diagnostics (PharmDx) Companion diagnostic tests designed to identify patients who are likely to respond to specific targeted therapies, helping clinicians determine the most effective treatment for cancer patients.
• Dako Molecular (Molecular Pathology) Molecular pathology solutions including in situ hybridization assays for detecting genetic alterations and biomarkers in cancer diagnostics for clinical laboratories.
• Dako Antibodies High-quality diagnostic antibodies and controls used in immunohistochemistry testing for identifying specific proteins and biomarkers in clinical and research laboratories.
• Dako Specific Proteins Reagents for detecting and measuring specific proteins in clinical samples, supporting quantitative diagnostic analysis in pathology laboratories.
• Dako Flow Cytometry Flow cytometry reagents and instruments for analyzing cell populations, used in clinical laboratories for cancer diagnostics and immunological profiling.
• Dako OEM Antibodies Original equipment manufacturer antibody products supplied to other diagnostic companies for integration into their testing platforms and instruments.

Named customers2 records

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature8 records

Partnerships

One partnership is on record.

• Agilent TechnologiescoreStrategic or Co-development PartnerDako is a wholly-owned brand of Agilent Technologies, a global leader in life sciences, diagnostics, and applied chemistry. Agilent acquired Dako to strengthen its pathology and companion diagnostics portfolio.

Scale indicators3 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Roche Diagnostics (Ventana): Roche's Ventana division is the leading direct competitor in IHC and companion diagnostics, offering an overlapping portfolio of tissue staining reagents, automated staining instruments, and FDA-approved CDx assays sold to the same hospital and reference laboratory customers.
• Leica Biosystems (Danaher): Leica offers pathology instruments, IHC reagents, and histology workflow solutions directly competitive with Dako's H&E, IHC, and special stains lines, serving the same clinical pathology laboratories globally.
• Bio-Rad Laboratories: Bio-Rad sells diagnostic reagents, antibodies, and quality controls used in clinical laboratories, with significant overlap in IHC antibodies, specific protein reagents, and flow cytometry consumables similar to Dako's reagent catalog.
• Bio-Techne: Bio-Techne's ProteinSimple and diagnostics segments produce antibodies, reagents, and analytical tools for pathology and cell analysis, directly competing with Dako's antibody, specific protein, and flow cytometry product lines.
• Qiagen: Qiagen provides molecular diagnostic assays and sample technologies for cancer detection and companion diagnostics, overlapping with Dako's molecular pathology and ISH offerings for biomarker-driven oncology testing.
• Becton, Dickinson and Company (BD): BD is a major provider of flow cytometry instruments and clinical immunology reagents used in cancer diagnostics, directly comparable to Dako's flow cytometry reagent portfolio serving hospital and reference labs.
• Sysmex: Sysmex is a leading provider of clinical flow cytometry, hematology, and cell analysis systems for hospital laboratories, directly competing with Dako's flow cytometry reagent and instrument business.

Broad incumbents

• Abbott Diagnostics: Abbott is a large diversified diagnostics incumbent with companion diagnostics, immunohistochemistry, and molecular pathology capabilities that overlap with Dako's PharmDx and molecular offerings in oncology.
• Hologic: Hologic's diagnostics division provides molecular and tissue-based diagnostic assays for oncology and women's health, with overlapping capabilities in molecular pathology and ISH-style detection relevant to Dako's oncology customer base.
• Danaher (Beckman Coulter Diagnostics): Danaher owns Leica Biosystems, Beckman Coulter, and Cepheid, providing a broad diagnostics and pathology platform that competes with Dako across IHC, special stains, flow cytometry, and molecular diagnostics.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A2 records

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Dako Denmark